9 Results for "

chemotype

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "chemotype" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-119464
CAS No.: 1392809-08-3
Purity:  98.18%
Target:  

ROR

Research Areas:  

Cancer

MRL-871 (compound 3) is a potent and allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists with an IC50 of 12.7 nM. MRL-871 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells .
loading...
    loading...
Cat. No.: HY-124424
CAS No.: 333415-38-6
Purity:  99.71%
Target:  

Potassium Channel

Research Areas:  

Others Neurological Disease

VU0071063 is a potent and specific Kir6.2/SUR1 opener (EC50=7.44 μM) and can be used for investigating Kir6.2/SUR1 expressed in the pancreas and brain. VU0071063 inhibits insulin secretion by inducing hyperpolarization of β-cell membrane potential. VU0071063 chemotype has a very steep structure-activity relationships .
loading...
    loading...
Cat. No.: HY-141515
CAS No.: 313671-26-0
Purity:  98.89%
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

BMS-986121 is a positive allosteric modulator (PAM) of the μ opioid receptor extracted from patent WO2014107344. BMS-986121 is built on a chemical scaffold representing a new chemotype for μ receptor PAMs .
loading...
    loading...
Cat. No.: HY-124482
CAS No.: 25516-15-8
Target:  

Others

Research Areas:  

Others

Mesembrenol (Chemotype c) is an alkaloid widely found in plants. Mesembrenol has potential application in quality control of raw materials and products of S.tortuosum .
loading...
    loading...
Cat. No.: HY-133128
CAS No.: 2407981-35-3
Target:  

ROR

Research Areas:  

Cancer

FM26 (compound 25) is a potent and allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists with an IC50 of 264 nM. FM26 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells .
loading...
    loading...
Cat. No.: HY-W718719
CAS No.: 508-32-7
Tricyclene is a natural bicyclic monoterpene hydrocarbon, and it is one of the main components in the essential oil of Salvia aegyptiaca L .
loading...
    loading...
Cat. No.: HY-139863
CAS No.: 3031364-03-8
Target:  

Bacterial

Research Areas:  

Infection

Antibacterial agent 62 is a novel redox cycling antituberculosis chemotype with potent bactericidal activity against growing and nutrient-starved phenotypically drug-resistant nongrowing bacteria.
loading...
    loading...
Cat. No.: HY-183444
CAS No.: 6902-62-1
Furanopetasin is an eremophilane-type sesquiterpene ester found in Petasites hybridus .
loading...
    loading...
Cat. No.: HY-L943
37030 compounds

MCE-18 stands for Medicinal Chemistry Evolution 2018, which was first published in Journal of Medicinal Chemistry in 2019 for assessing molecular novelty and three-dimensional complexity. Developed based on Clarivate global pharmaceutical patent database, this descriptor was constructed via big-data analysis covering 28,161 patented lead compounds, 1,370 approved drugs and nearly 30,000 preclinical-to-phase III drug candidates from 23 top pharmaceutical companies worldwide between 1950 and 2018, followed by structural clustering and removal of redundant outdated scaffolds for data denoising. Its scoring system integrates five core structural features including aromatic ring (AR), aliphatic heterocycle (NAR), chiral center (CHIRAL), spiro atom (SPIRO), cyclic and acyclic sp³ carbon ratio together with a quadratic topological correction factor. Breaking the limitations of the single Fsp³ parameter, MCE-18 effectively distinguishes conventional flat aromatic scaffolds from modern 3D-enriched novel chemotypes, overcoming typical drawbacks of traditional compound libraries such as scaffold redundancy, low screening hit rates and poor compatibility with allosteric and PPI-related difficult targets.

This library contains over 37,000 structurally diverse compounds with favorable overall drug-likeness, suitable for high-throughput screening against canonical targets including kinases, GPCRs and proteases as well as challenging allosteric and PPI targets. Compounds comply with the developmental trend of modern novel drug discovery, supporting routine primary screening as well as early hit identification of allosteric modulators and PPI inhibitors, serving as an efficient screening resource for early-stage innovative drug discovery.